CLINUVEL PHARMACEUT. ORDINARY (CUV) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXCLINUVEL update on Level II ADR upgrade, Nasdaq uplist
other announcement
Final EMA scientific advice for pivotal Phase III vitiligo
other announcement
CLINUVEL Investor Webinar Half Year Results December 2025
other announcement
StockheadHealth Check: Cash is king in these troubled times, declares defiant Clinuvel
Skin disorders house Clinivel says a huge cash stockpile protects the company from "externalities" and enables its programs to be ... Read More The post Health Check: Cash is king in these troubled times, declares defiant Clinuvel appeared first on Stockhead.
CLINUVEL Record Revenues, Advances Strategic Expansion
earnings announcement
CLINUVEL - injectable peptide platform in preclinical study
other announcement
SCENESSE efficacy in vitiligo - new cases presented at RDTC
other announcement
CLINUVEL progresses Level II ADR upgrade, Nasdaq uplist
other announcement
CLINUVEL advances NEURACTHEL Instant, EU filing mid-2026
other announcement
Health Canada requests additional time for SCENESSE review
other announcement
CLINUVEL advances new formulations in preclinical program
other announcement
SCENESSE efficacy in vitiligo - new cases presented to EADV
other announcement
CLINUVEL delivers ninth consecutive revenues growth & profit
earnings announcement
Appendix 4E and Annual Report to Shareholders 2025
other announcement
CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
other announcement
Study confirms NB-UVB needed to activate repigmentation
other announcement